Although we support the need for regulatory guidelines in India and other medical tourism destinations, we believe that such guidelines must be coupled with guidelines in source countries as part of a comprehensive and global approach. If these guidelines are developed piecemeal they risk being less effective or not implemented owing to worries that less regulated countries will develop pricing advantages.

We declare that we have no conflicts of interest.

*Valorie A Crooks, Jeremy Snyder crooks@sfu.ca
Department of Geography, Simon Fraser University, Burnaby, BC V5A 1S6, Canada

1 Shetty P. Medical tourism booms in India, but at what cost? Lancet 2010; 376: 671–72.

A David Smith
david.smith@pharm.ox.ac.uk
Oxford Project to Investigate Memory and Ageing (OPTIMA) and Department of Pharmacology, University of Oxford, Oxford OX1 3QT, UK

Why are drug trials in Alzheimer’s disease failing?

You suggest several reasons why trials in Alzheimer’s disease are failing (Aug 28, p 658), but you do not consider an obvious one: that the hypothesis on which most Alzheimer’s trials are based might not be valid.

If a scientist does several experiments on the basis of a hypothesis and they all fail, he will abandon the hypothesis. Why are we so reluctant to do this in medicine? The dominant hypothesis in the field is the amyloid hypothesis and almost all trials of potential disease-modifying drugs are based on manipulation of β amyloid. In the recently abandoned semagacestat trial, some patients on the drug got worse—ie, the drug, which was designed to inhibit formation of β amyloid, seemed to speed up cognitive decline. One interpretation is that the formation of β amyloid might be the brain’s protective mechanism against the disease process. But this view is regarded as pure heresy. Is that because so much research funding and such large drug development budgets are at stake?

The review by Mangialasche and colleagues concluded that “the one protein, one drug, one disease hypothesis used as a basis of most Alzheimer’s disease therapy studies needs to be revised.” It is time that we stopped looking for a “cure” but directed our research effort to the prevention of Alzheimer’s disease. This complex disease will yield not to a single drug but to multiple approaches to modify the disease process, starting in mid-life. Two examples of hopeful avenues are the treatment of hypertension in mid-life and the lowering of homocysteine early in the disease process.

I declare that I have no conflicts of interest.

A David Smith
david.smith@pharm.ox.ac.uk
Oxford Project to Investigate Memory and Ageing (OPTIMA) and Department of Pharmacology, University of Oxford, Oxford OX1 3QT, UK